Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)

Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)

Abstract Background Primary systemic vasculitis (PSV) is a heterogeneous group of autoimmune conditions. There is an unmet need for alternative therapies that lead to sustained remission in patients with refractory disease. Alemtuzumab, an anti-CD52 antibody, depletes lymphocytes for prolonged perio...

Full description

Bibliographic Details
Main Authors: Seerapani Gopaluni, Rona Smith, Donna Goymer, Hugh Cahill, Elizabeth Broadhurst, Elizabeth Wallin, Mark McClure, Afzal Chaudhry, David Jayne
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Arthritis Research & Therapy
Subjects:
ANCA
Alemtuzumab
Vasculitis
Behçet’s disease
Clinical trial
T cells
Online Access:https://doi.org/10.1186/s13075-022-02761-6

Internet

https://doi.org/10.1186/s13075-022-02761-6

Similar Items